Glasdegib is a sonic hedgehog receptor inhibitor used to treat newly diagnosed acute myeloid leukemia in patients over 75 years who cannot receive intense chemotherapy. Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles.
- Mechanism
- Curator reviewed · 2 references
Glasdegib is a potent and selective inhibitor of the hedgehog signaling pathway that acts by binding to the smoothened (SMO) receptor.
The hedgehog signaling pathway is involved in maintenance of neural and skin stem cells. In this pathway, the binding of specific ligands to the transmembrane receptor patched (PTCH1) allows the activation of the transcriptional regulators GL11, GL12 and modulation of the gene expression through SMO-mediated signaling. The aberrant activation of the hedgehog pathway is thought to be implicated in the pathogenesis of chronic myeloid leukemia, medulloblastoma and basal cell carcinoma due to the hyperproliferative state that a modification on this pathway will produce.
- Primary indication
- Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy.Curator reviewed · 2 structured indications
- Formula / weight
- C21H22N6O · 374.448 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2018 · European Union, 2021
- Code names
- PF-04449913 · PF-4449913
- Brand names
Resolves to
SFNSLLSYNZWZQG-VQIMIIECSA-NSMILESCN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#NWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Glasdegib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account